Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)‘s stock had its “outperform” rating reiterated by equities research analysts at BMO Capital Markets in a report released on Wednesday. They currently have a $13.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $12.00. BMO Capital Markets’ target price points to a potential upside of 88.41% from the stock’s previous close.

TTPH has been the subject of several other reports. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. HC Wainwright initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They set a “buy” rating and a $15.00 price objective for the company. Finally, Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from $8.00 to $15.00 in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $10.25.

Shares of Tetraphase Pharmaceuticals (TTPH) traded up 19.5406% during trading on Wednesday, hitting $8.2483. The stock had a trading volume of 8,298,278 shares. The stock’s market capitalization is $313.07 million. The stock’s 50-day moving average is $7.47 and its 200-day moving average is $6.81. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The firm had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.46 million. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. The firm’s revenue for the quarter was down 24.5% on a year-over-year basis. Analysts predict that Tetraphase Pharmaceuticals will post ($2.74) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Tetraphase Pharmaceuticals, Inc. (TTPH) Stock Rating Reaffirmed by BMO Capital Markets” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/07/26/tetraphase-pharmaceuticals-inc-ttph-stock-rating-reaffirmed-by-bmo-capital-markets.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP increased its position in shares of Tetraphase Pharmaceuticals by 90.2% in the fourth quarter. GSA Capital Partners LLP now owns 33,600 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 15,931 shares during the period. Wade G W & Inc. bought a new position in shares of Tetraphase Pharmaceuticals during the first quarter valued at about $138,000. Teza Capital Management LLC increased its position in shares of Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,281 shares during the period. Citadel Advisors LLC increased its position in shares of Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 2,496 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in shares of Tetraphase Pharmaceuticals during the fourth quarter valued at about $156,000. Institutional investors own 46.24% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.